Press releaseBusiness Wire
Guardant Health
GH · NASDAQ
$162.59+$4.71 (+2.98%)TodayMarket closed ·
Prev close $157.88
Latest news
- Press releaseBusiness Wire
TwinStrand Biosciences Announces Second U.S. Patent Trial and Appeal Board Decision Upholding All Claims of TwinStrand’s ‘127 Patent
- Press releaseBusiness Wire
Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests
- Press releaseBusiness Wire
Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer
- Press releaseBusiness Wire
Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026
- NewsPiero Cingari
S&P 500, Nasdaq Hit Records, Power Stocks Rally on Google's Nuclear Deal: Stock Market Today
- Press releaseBusiness Wire
Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma
- Press releaseBusiness Wire
Guardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening
- Press releaseBusiness Wire
Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer
- Press releaseBusiness Wire
Business Insider Names Guardant Health One of America's Most Innovative Businesses
- Press releaseBusiness Wire
Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer
- NewsChandrima Sanyal
Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
- Press releaseBusiness Wire
Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening
- Press releaseBusiness Wire
Guardant Health to Appeal Federal District Court Judgment
- NewsVandana Singh
Guardant Health Hit With Ongoing Royalties Over Duplex Sequencing Tech
- Press releaseBusiness Wire
TwinStrand Biosciences Announces Final Judgment in Patent Infringement Suit Against Guardant Health, Awarding TwinStrand and the University of Washington More Than $245.2 Million in Damages, Accrued Royalties and Interest
- Press releaseBusiness Wire
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- NewsAvi Kapoor
AXT Posts Upbeat Q2 Earnings, Joins Newell Brands, SPX Technologies, Amazon And Other Big Stocks Moving Higher On Friday
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- Press releaseBusiness Wire
Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
- Press releaseBusiness Wire
Guardant Health to Participate in Upcoming Investor Conferences
- Press releaseBusiness Wire
Actor and Cancer Advocate Patrick Dempsey Stars in Emotional Tribute Video From Guardant Health Memorializing Those Who Have Lost Their Lives to Colorectal Cancer
- Press releaseBusiness Wire
Guardant Health to Report Second Quarter 2026 Financial Results on July 30, 2026
- Press releaseBusiness Wire
UnitedHealth Group Now Covers Guardant Health’s Shield Blood Test for Colorectal Cancer Screening
- Press releaseBusiness Wire
Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim's HERNEXEOS®
- Press releaseBusiness Wire
Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting
- Press releaseBusiness Wire
American Cancer Society Recommends Guardant Health's Shield Blood Test in Updated Colorectal Cancer Screening Guidelines
- NewsNabaparna Bhattacharya
D-Wave, Dell, And IonQ Are Among Top 10 Large-Cap Gainers Last Week (May 18-May 22): Are the Others in Your Portfolio?
- NewsVandana Singh
Guardant Health Secures FDA Approval For Expanded Liquid Biopsy Test
- Press releaseBusiness Wire
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
- Press releaseBusiness Wire
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Press releaseBusiness Wire
Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
- NewsVandana Singh
Pfizer, Arvinas Win FDA Nod For First-Of-Its-Kind Breast Cancer Therapy
- News
Guardant Health And Nuvalent Enter Strategic Collaboration For The Development And Potential Commercialization Of Nuvalent's Oncology Pipeline Using The Guardant Infinity Platform's Tissue And Liquid Tools
- Press releaseBusiness Wire
Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform
- Press releaseBusiness Wire
Guardant Health's InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan
- Press releasePRNewswire
Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data
- Press releaseBusiness Wire
Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
- News
Earnings Scheduled For February 19, 2026
- NewsVandana Singh
FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal Cancer
- Press releaseBusiness Wire
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results
- NewsAvi Kapoor
Nutex Health Posts Strong Q3 Results, Joins PACS Group, Walmart, Cerence And Other Big Stocks Moving Higher On Thursday
- News
6 Healthcare Stocks With Strong Upward Momentum
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.